Alphabet’s artificial intelligence start-up Isomorphic Labs has made a splash at the start of the JP Morgan Healthcare conference this week, announcing its first pharma pa
Novartis has doubled down on its gene therapy collaboration with Voyager Therapeutics, stumping up another $1.2 billion-plus in potential milestone payments and directing
Pfizer’s once-weekly antibody injection for haemophilia A and B, marstacimab, could be on track for regulatory approvals based on solid results in a phase 3 trial reported
Just days after getting FDA approval for Fabhalta as the first oral therapy for paroxysmal nocturnal haemoglobinuria (PNH), Novartis has reported new data showing it is al
Novartis has settled a lawsuit brought by Daiichi Sankyo’s Plexxikon subsidiary, paying $180 million to resolve claims that its Tafinlar cancer drug infringed US patents h
Novartis’ targeted factor B inhibitor iptacopan has become the first oral monotherapy to be approved by the FDA for rare blood disorder paroxysmal nocturnal haemoglobinuri